在切换至长效卡博特韦和利匹韦林的HIV-1患者中，无口服导入期时卡博特韦谷浓度较低。
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
作者信息
Rubenstein Emma, Diemer Myriam, Goldwirt Lauriane, Lascoux-Combe Caroline, Chaix Marie-Laure, Rami Agathe, Ponscarme Diane, Lafaurie Matthieu, Denis Blandine, De Castro Nathalie, Gras Julien, Liegeon Geoffroy, Sellier Pierre-Olivier, Deville Laure, Chevret Sylvie, Delaugerre Constance, Molina Jean-Michel
机构信息
Department of Infectious Diseases, Saint Louis and Lariboisiere Hospitals, Université Paris Cité.
Department of Pharmacology.
出版信息
AIDS. 2024 Jul 1;38(8):1267-1269. doi: 10.1097/QAD.0000000000003887. Epub 2024 May 30.
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007).
在一组72例连续的病毒学抑制的HIV-1患者中，他们换用了长效卡博特韦和rilpivirine，我们观察到首次注射后1个月和3个月时卡博特韦的谷浓度较低，且与1个月时未进行口服导入显著相关[比值比（OR）=6.3[95%置信区间（CI）1.7-29.5]，P=0.01]以及3个月时（OR=5.6[95%CI 1.3-29.7]，P=0.03），还与1个月时的高体重指数相关（OR=1.3[95%CI 1.1-1.6]，P=0.007）。
Zotero 插件